Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medical therapy for ulcerative colitis.

S B Hanauer1

  • 1Section of Gastroenterology and Hepatology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA. shanauer@medicine.bsd.uchicago.edu

Current Opinion in Gastroenterology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).

Alimentary pharmacology & therapeutics·2018
Same author

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Alimentary pharmacology & therapeutics·2017
Same author

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.

Alimentary pharmacology & therapeutics·2013
Same author

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.

Alimentary pharmacology & therapeutics·2013
Same author

Treatment of perianal Crohn's disease: a medical approach.

Inflammatory bowel diseases·2013

Medical therapy for ulcerative colitis saw limited advancements last year, prompting interest in alternative treatments like aminosalicylates, immune modifiers, and novel approaches targeting inflammation.

Area of Science:

  • Gastroenterology and Internal Medicine
  • Inflammatory Bowel Disease Research

Background:

  • Ulcerative colitis (UC) treatment options saw minimal progress in the past year.
  • This contrasts with advancements in Crohn's disease therapies, leading UC patients to explore alternative options.
  • Existing treatments for UC include aminosalicylates and immune modifiers.

Purpose of the Study:

  • To review recent developments in ulcerative colitis therapy.
  • To highlight advances in established and nonconventional treatment approaches for UC.
  • To discuss emerging therapeutic targets derived from preclinical research.

Main Methods:

  • Review of recent literature on ulcerative colitis treatments.
  • Analysis of advances in aminosalicylates and immune modifiers.

Related Experiment Videos

  • Exploration of nonconventional therapies and novel targets.

    • Main Results:

    • Therapeutic developments for ulcerative colitis were incremental rather than revolutionary.
    • Advances were noted in the application of aminosalicylates and immune modifiers.
    • Nonconventional approaches such as nicotine, probiotics, dietary therapies, and heparins are being explored.
    • Preclinical research identified novel targets like nuclear factor-kappaB and tumor necrosis factor-alpha.

    Conclusions:

    • Ulcerative colitis treatment remains an area needing significant innovation.
    • Established therapies show incremental progress, while nonconventional methods gain attention.
    • Future UC therapies may leverage novel targets identified in animal models, such as inhibiting nuclear factor-kappaB and targeting tumor necrosis factor-alpha.